November 15, 2024

The Public Editor: Repairing the Credibility Cracks After Jayson Blair

Jayson Blair, a young Times reporter, lied and faked and cheated his way through story after story — scores of them, for years. He fabricated sources, plagiarized material from other publications, and pretended to be places he never went. The problem, once fully investigated and made public by The Times itself, brought down not only the reporter but also The Times’s executive editor and managing editor. For a while, it even made The Times a laughingstock in late-night comedy routines.

“I think of Jayson Blair as an accident that ended my newspaper career in the same unpredictable way that a heart attack or a plane crash might have,” Howell Raines, that executive editor, wrote a year later in a long, fascinating piece for The Atlantic. Last week, when I interviewed him by phone, Mr. Raines made a similar comparison: “It was like stepping on a land mine.” The result, he said, “was heartbreaking for me.”

It was also, as the publisher, Arthur O. Sulzberger Jr., put it, “a huge black eye” for The Times. Glenn Kramon, who was the business editor at the time and helped in the paper’s exhaustive investigation of Mr. Blair’s wrongdoings, remembers just how brutal that period was: “I didn’t realize how bad things had become until the P.R. guy from Enron called to tell us to hang in there.” And he remembers the emotions: “I felt anger on behalf of the 400 or so scrupulous, dedicated reporters who were incapable of such behavior.”

Much has happened since, and The Times is in its second round of new editorial leadership. But even now, when newspaper companies are preoccupied with long-term survival, it is still a touchy subject.

After the scandal and a thorough internal analysis, Times management put safeguards in place. One was the role of the public editor — I am the fifth — to give readers a direct place, independent of The Times’s editing structure, to take complaints about journalistic integrity. Another was the creation of a full-time standards editor, an internal position within the newsroom hierarchy. Still another was a program to thoroughly and regularly evaluate journalists’ work.

But, despite all of this, could a similar episode — or something as damaging — happen again?

“You have to always believe that something awful could happen again,” the executive editor, Jill Abramson, told me last week. Both she and the managing editor, Dean Baquet, pointed out that the particulars of the Blair problems — repeated fabrication and lying in articles — would come to the surface much more quickly in the age of blogging and Twitter.

“The world is better at checking us and challenging us,” Mr. Baquet said. “But it would be arrogant to say something couldn’t happen.”

Though plagiarism and fabrication remain a worry for editors, more likely these days is a problem that could arise from the misuse of social media, in which journalists have unfiltered, unedited publication channels. And beyond the actions of individual journalists, The Times faces previously unimagined risks to its credibility as it experiments with new ways to replace advertising revenue, which continues to shrink. For instance, the company has said that it will run more events like last year’s DealBook conference, in which outsiders pay to attend, allowing them unusal access to Times journalists. Such events are relatively harmless — certainly not sins on the order of the Blair scandal — but the meshing of journalism and moneymaking raises the potential for conflict-of-interest trouble.

Ms. Abramson said that one of the greatest lessons of the Blair scandal was “how concerned, hurt and angry our readers were, because this was contrary to everything we stand for — the trust and authenticity that people attach to The Times.”

Clyde Haberman, the celebrated reporter and columnist who retired recently, called the episode “without question the worst period in my 36 years at the paper.” As bad as it was, though, he said that it underlined for him a continuing virtue of the journalistic world: the importance of trust between reporter and editor, and between the paper and its readers.

“Trust is the coin of our realm,” he said. “We trust that the people we interview are being straight with us. We trust that our confidential sources are decent folks. We trust that our reporters went to the places they say they went, and spoke with the people they say they met. Naturally, trust doesn’t mean blind faith. Trust but verify, as Ronald Reagan said in a different context. But generally speaking, we are no different from anyone else on this planet: We accept that the people we deal with, and work with, are honorable.”

Article source: http://www.nytimes.com/2013/05/05/public-editor/repairing-the-credibility-cracks-after-jayson-blair.html?partner=rss&emc=rss

New Drugs Fight Prostate Cancer, but at High Cost

In the last 15 months, three new drugs that extended the lives of prostate cancer patients in clinical trials have been approved by the Food and Drug Administration and several other promising medicines are in clinical trials. Before last year, only one drug had been shown to improve survival — docetaxel, which was approved in 2004.

“What a great time it is in prostate cancer,” Dr. Daniel J. George of the Duke Cancer Institute proclaimed earlier this month at the annual meeting of the American Society of Clinical Oncology.

And it’s a great time for the drug makers, with several drugs competing to fill a niche for longer-term survival. Analysts estimate that some of the new drugs, particularly Dendreon’s Provenge and Johnson Johnson’s Zytiga, could reach annual sales of $1 billion or even much more.

The recently approved drugs and most of those in development are for cases in which the disease has spread beyond the prostate gland and is no longer held in check by hormone therapy.

Men with that late-stage cancer had a median survival of about a year and a half using docetaxel. The new drugs each added two to five months to median survival when tested in clinical trials. Doctors say that men taking more than one of the drugs in succession would be expected to live more than two years.

But the price of these drugs has already stirred concerns about the costs of care among patients, providers and insurers. For example, Provenge costs $93,000 for a course of treatment, while Zytiga costs about $5,000 a month. Another of the new drugs, Sanofi’s Jevtana, costs about $8,000 every three weeks.

With other pricey drugs on the way, said Joel Sendek, an analyst at Lazard, “We could be talking easily $500,000 per patient or more over the course of therapy, which I don’t think the system can afford, especially since 80 percent of the patients are on Medicare.”

Medicare has already fired what some analysts interpret as a warning shot over prices, conducting a yearlong inquiry into whether to pay for Provenge. In its final decision, due Thursday, Medicare is expected to pay for the drug when used according to the label.

Medicare officials denied that price was the reason for the review. But some patient advocates and politicians portrayed the review as a step toward rationing.

Private insurers are also paying only if drugs are used according to the label, according to doctors and patient advocates.

“The reality is, there’s pushback,” said Dr. Oliver Sartor of Tulane University.

Still, for now, one company’s price is prompting the next one to follow suit.

“The pricing environment is encouraging and getting better for us,” Andrew Kay, the chief executive of Algeta, told securities analysts earlier this month, after announcing that his company’s experimental drug had extended median survival nearly three months in a clinical trial.

Mr. Kay said he had initially thought that his company, which is based in Norway, would charge about $25,000 for a typical course of treatment with the drug, Alpharadin. But with the rival drug Jevtana costing about $50,000, Algeta and its partner, Bayer, are considering a higher price.

About 218,000 men in the United States get prostate cancer each year and about 32,000 die, according to the American Cancer Society.

In many cases, the cancer is caught before it has spread beyond the prostate gland and can be cured with surgery or radiation therapy.

If the cancer has spread, men usually are given drugs, particularly Abbott Laboratories’ Lupron, that suppress the body’s production of the hormone testosterone, which can fuel tumor growth.

The new drugs, for now at least, are for use when this hormone-deprivation therapy has stopped working.

“This is a small subset of people with prostate cancer,” said Dr. Charles Myers, a prostate cancer specialist in private practice in Charlottesville, Va., who is a survivor of the disease himself. However, he noted, “It’s the group of people who are dying.”

Provenge was approved in April 2010 for patients whose cancer was late-stage but not yet causing many symptoms.

Once symptoms, mainly bone pain, have appeared, men are likely to receive docetaxel, a generic drug also sold by Sanofi as Taxotere .

Two other new drugs are approved for use only after docetaxel has been tried. One, Sanofi’s Jevtana, is a chemotherapy drug in the same class as docetaxel; it was approved in June 2010. The other is Johnson Johnson’s Zytiga, approved this April.

Article source: http://feeds.nytimes.com/click.phdo?i=8ee3f8ee2579e158794cf17812f4791b